<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03408392</url>
  </required_header>
  <id_info>
    <org_study_id>205731</org_study_id>
    <nct_id>NCT03408392</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions</brief_title>
  <official_title>An Open-label, Randomised, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of SKF101804 Cefixime 200 mg/5 mL Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Participants Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open-label, randomized two-way cross-over study to determine if cefixime 200
      mg/5 mL powder for suspension (test formulation: SKF101804) is bioequivalent to cefixime 200
      mg/5 mL suspension reference formulation. Study will be conducted in 28 healthy adult
      subjects under fasting conditions. There will be two treatment periods and each subject will
      participate in both periods. The washout period between both treatment periods will be 7-14
      days. Subjects will be randomized to either of treatment sequences of reference followed by
      test or test followed by reference to receive a single dose of test or reference formulation
      on Day 1 in each treatment period. The study will last for 5 to 7 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Actual">March 13, 2018</completion_date>
  <primary_completion_date type="Actual">March 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) for Cefixime</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods. Pharmacokinetic Population comprised of participants who completed the study and for whom primary pharmacokinetic parameters could be calculated for all treatment periods were included in the statistical pharmacokinetic analysis of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) Within a Participant Across All Treatments of Cefixime</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to (AUC [0-infinity]) Across All Treatments for Cefixime</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax) for Cefixime</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of ciprofloxacin was conducted using non-compartmental methods. Tmax of cefixime was analyzed using a nonparametric test to compute point estimate of the median and full range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC(0-infinity) Obtained by Extrapolation (%AUCex) for Cefixime</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Half-life (T1/2) for Cefixime</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-serious Adverse Events (AE) and Serious Adverse Events (SAE)</measure>
    <time_frame>Up to Day 16 in each treatment period</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/ incapacity, is a congenital anomaly/ birth defect or other situations. The analysis was performed on Safety Population which comprised of all randomized participants who received at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), and Aspartate Aminotransferase (AST) at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including ALT, ALP and AST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen (BUN) at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of BUN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Glucose, Potassium and Sodium at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including calcium, glucose, potassium and sodium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin (Total Bil), Direct Bilirubin (Direct Bil) and Creatinine (Creat) at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including total bil, direct bil and creat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Protein at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of total Protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets, Neutrophils, Monocytes, Lymphocytes, Leucocyte, Eosinophils and Basophils at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematology parameters including platelets, neutrophils, monocytes, lymphocytes, leucocyte, eosinophils and basophils.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Volume (MCV) at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Hemoglobin (MCH) at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Count at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of erythrocyte count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematocrit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb) at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematology parameters including MCHC and Hb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reticulocytes at Indicated Time-points</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of percent reticulocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potential Clinical Importance (PCI) Abnormal Findings for Urinalysis</measure>
    <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
    <description>Urine samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2. PCI ranges for urinalysis parameters were as follows: specific gravity 1.001 to 1.035 kilogram per liter, blood negative (0 to 9) RBC per microliter, pH 4.6 to 8.0, protein negative (0.0 to 0.14) gram per liter, glucose negative (0 to 5.49) millimoles per liter, ketones negative (0.0 to 0.49) millimoles per liter, urobilinogen (0.0 to 1.0) milligrams per deciliter, urine leucocytes negative (0 to 14) leucocytes per microliter, Urine WBC, RBC and epithelial cells 0 to 5 high power per field.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate at Indicated Time-points</measure>
    <time_frame>Day 1 Pre-dose 1.5 hours, Day 1 post-dose 2, 4, and 6 hours and Day 2 post-dose 24 hours of each treatment period</time_frame>
    <description>Respiratory rate of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate at Indicated Time-points</measure>
    <time_frame>Day 1 Pre-dose 1.5 hours, Day 1 post-dose 2, 4, and 6 hours and Day 2 post-dose 24 hours of each treatment period</time_frame>
    <description>Pulse rate of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature at Indicated Time-points</measure>
    <time_frame>Day 1 Pre-dose 1.5 hours, Day 1 post-dose 2, 4, and 6 hours and Day 2 post-dose 24 hours of each treatment period</time_frame>
    <description>Body temperature of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time-points</measure>
    <time_frame>Day 1 Pre-dose 1.5 hours, Day 1 post-dose 2, 4, and 6 hours and Day 2 post-dose 24 hours of each treatment period</time_frame>
    <description>Blood pressure of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Infections, Bacterial</condition>
  <arm_group>
    <arm_group_label>Test followed by Reference Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference followed by Test Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation A</intervention_name>
    <description>Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.</description>
    <arm_group_label>Reference followed by Test Formulation</arm_group_label>
    <arm_group_label>Test followed by Reference Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference formulation B</intervention_name>
    <description>Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.</description>
    <arm_group_label>Reference followed by Test Formulation</arm_group_label>
    <arm_group_label>Test followed by Reference Formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 18 to 65 years of age inclusive, at the time of signing the informed
             consent.

          -  Subject must be healthy, non-smoker, as determined by the investigator or medically
             qualified designee based on a medical evaluation including medical history, physical
             examination, laboratory tests, and cardiac monitoring.

          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not
             specifically listed in the inclusion or exclusion criteria, outside the normal
             reference range for the population being studied may be included at investigator
             discretion in consultation with the Medical Monitor if required, agree and document
             that the finding is unlikely to introduce additional risk factors and will not
             interfere with the study procedures.

          -  Subject with a body weight 50 kilogram (kg) and body mass index (BMI) within the range
             19-30 kilogram per meter square (kg/m^2) (inclusive).

          -  A healthy male subject must agree to use contraception during the treatment period and
             for at least 5 days after the last dose of study treatment and refrain from donating
             sperm during this period.

          -  A female subject is eligible to participate if she is not pregnant, not breastfeeding,
             not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the
             contraceptive guidance during the treatment period and for at least 30 days after the
             last dose of study treatment.

          -  A subject should be capable of giving signed informed consent.

        Exclusion Criteria:

          -  Subject with history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs;
             constituting a risk when taking the study treatment; or interfering with the
             interpretation of data.

          -  Subjects with any other condition that is capable of significantly altering the
             absorption, metabolism, or elimination of drugs; constituting a risk when taking the
             study treatment; or interfering with the interpretation of data.

          -  Subject with abnormal renal function, as determined by creatinine clearance and
             considered as clinically significant by the investigator will be excluded.

          -  Subject with abnormal blood pressure (BP) as determined by the investigator.

          -  Subject with lymphoma, leukemia, or any malignancy within the past 5 years except for
             basal cell or squamous epithelial carcinomas of the skin that have been resected with
             no evidence of metastatic disease for 3 years.

          -  Subject who had breast cancer within the past 10 years.

          -  ALT &gt;1.5 times upper limit of normal (ULN).

          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin
             is fractionated and direct bilirubin &lt;35%).

          -  Subject with current or chronic history of liver disease, or known hepatic or biliary
             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Subject with history of colitis

          -  Subject with history of cephalosporin induced hemolytic anemia.

          -  QT interval corrected for heart rate according to Bazett's formula (QTcB) &gt;450
             milliseconds (msec). Subjects with a known risk of QT prolongation will be excluded.

          -  Past or intended use of over-the-counter or prescription medication including herbal
             medications, within 14 days prior to dosing unless in the opinion of the investigator
             and sponsor, the medication will not interfere with the study.

          -  Participation in the study would result in loss of blood or blood products in excess
             of 500 mL within 90 days.

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Current enrolment or past participation within the last 90 days before signing of
             consent in this or any other clinical study involving an investigational study
             treatment or any other type of medical research.

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening. Positive Hepatitis C
             antibody test result at screening. Subjects with positive Hepatitis C antibody due to
             prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C
             ribonucleic acid (RNA) test is obtained.

          -  Positive pre-study drug/alcohol screen.

          -  Positive human immunodeficiency virus (HIV) antibody test.

          -  Regular use of known drugs of abuse.

          -  Subjects with regular alcohol consumption within 6 months prior to the study defined
             as: an average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit
             is equivalent to 8 gram (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1
             glass (125 mL) of wine or 1 (25 mL) measure of spirits.

          -  Subjects with urinary cotinine levels indicative of smoking or history or regular use
             of tobacco- or nicotine-containing products within 6 months prior to screening.

          -  Subjects who are sensitive to heparin or heparin-induced thrombocytopenia.

          -  Subjects with known sensitivity to any drugs from the class of cephalosporin, or
             components thereof.

          -  Subjects with known sensitivity to any drugs from the class of penicillin, or
             components thereof.

          -  Subjects with known sensitivity to any of the study treatments, or components thereof,
             or drug or other allergy that, in the opinion of the investigator or medical monitor,
             contraindicates participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <results_first_submitted>December 11, 2018</results_first_submitted>
  <results_first_submitted_qc>December 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2019</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single dose</keyword>
  <keyword>Oral suspension</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Cefixime</keyword>
  <keyword>Two-way crossover</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com/Posting.aspx?ID=20173</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT03408392/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open-label, randomized, single-dose, two-period cross-over study to evaluate bioequivalence of SKF101804 Cefixime 200 milligram (mg)/5 milliliter (mL) suspension versus Cefixime 200 mg/5 mL suspension reference product in healthy adult participants under fasting conditions. Participants were enrolled at a single center in South Africa.</recruitment_details>
      <pre_assignment_details>Participants received treatment in one of the two sequences; SKF101804 cefixime 200mg/5mL suspension (Test formulation) followed by cefixime 200mg/5mL suspension (Reference formulation)or vice versa in each of the treatment period 1 and 2. A total number of 28 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SKF101804 Cefixime Followed by Cefixime Reference Formulation</title>
          <description>Eligible participants received single dose of Test formulation (SKF101804 cefixime 200 mg /5 mL suspension) orally on Day 1 in Treatment period 1. It was followed by a washout period of at least 7 days and not more than 14 days. Participants received single dose of Reference formulation (cefixime 200 mg/5 mL suspension) orally on Day 1 in Treatment period 2.</description>
        </group>
        <group group_id="P2">
          <title>Cefixime Reference Formulation Followed by SKF101804 Cefixime</title>
          <description>Eligible participants received single dose of Reference formulation (cefixime 200 mg/5 mL suspension) orally on Day 1 in Treatment period 1. It was followed by a washout period of at least 7 days and not more than 14 days. Participants received single dose of Test formulation (SKF101804 cefixime 200 mg /5 mL suspension) orally on Day 1 in Treatment period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (16 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out Period (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (16 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Eligible participants received a single dose of Test formulation (SKF101804 cefixime 200 mg /5 mL suspension) followed by Reference formulation (cefixime 200 mg/5 mL suspension) or vice versa, administered orally on Day 1 in each treatment period 1 and 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mixed Race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) for Cefixime</title>
        <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods. Pharmacokinetic Population comprised of participants who completed the study and for whom primary pharmacokinetic parameters could be calculated for all treatment periods were included in the statistical pharmacokinetic analysis of the study.</description>
        <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) for Cefixime</title>
          <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods. Pharmacokinetic Population comprised of participants who completed the study and for whom primary pharmacokinetic parameters could be calculated for all treatment periods were included in the statistical pharmacokinetic analysis of the study.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20000" spread="32.9"/>
                    <measurement group_id="O2" value="19000" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bio-equivalence analysis comparing cefixime test and reference product has been presented.</non_inferiority_desc>
            <param_type>Percentage ratio</param_type>
            <param_value>105.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.11</ci_lower_limit>
            <ci_upper_limit>115.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) Within a Participant Across All Treatments of Cefixime</title>
        <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) Within a Participant Across All Treatments of Cefixime</title>
          <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2670" spread="29.4"/>
                    <measurement group_id="O2" value="2640" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bio-equivalence analysis comparing cefixime test and reference product has been presented.</non_inferiority_desc>
            <param_type>Percentage ratio</param_type>
            <param_value>101.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.37</ci_lower_limit>
            <ci_upper_limit>109.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to (AUC [0-infinity]) Across All Treatments for Cefixime</title>
        <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to (AUC [0-infinity]) Across All Treatments for Cefixime</title>
          <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20700" spread="31.8"/>
                    <measurement group_id="O2" value="19700" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bio-equivalence analysis comparing cefixime test and reference product has been presented.</non_inferiority_desc>
            <param_type>Percentage ratio</param_type>
            <param_value>105.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.31</ci_lower_limit>
            <ci_upper_limit>114.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Occurrence of Cmax (Tmax) for Cefixime</title>
        <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of ciprofloxacin was conducted using non-compartmental methods. Tmax of cefixime was analyzed using a nonparametric test to compute point estimate of the median and full range.</description>
        <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Cmax (Tmax) for Cefixime</title>
          <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of ciprofloxacin was conducted using non-compartmental methods. Tmax of cefixime was analyzed using a nonparametric test to compute point estimate of the median and full range.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.005" lower_limit="2.50" upper_limit="6.02"/>
                    <measurement group_id="O2" value="4.005" lower_limit="2.02" upper_limit="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of AUC(0-infinity) Obtained by Extrapolation (%AUCex) for Cefixime</title>
        <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of AUC(0-infinity) Obtained by Extrapolation (%AUCex) for Cefixime</title>
          <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Percentage of AUCex</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="51.4"/>
                    <measurement group_id="O2" value="3.32" spread="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Half-life (T1/2) for Cefixime</title>
        <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0 8.0, 10.0, 12.0, 16.0 and 20.0 hours post dose on Day 1, 24.00 hours post dose on Day 2 of each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Half-life (T1/2) for Cefixime</title>
          <description>Blood samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of cefixime under fasted state. Pharmacokinetic analysis of cefixime was conducted using non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="15.0"/>
                    <measurement group_id="O2" value="3.13" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-serious Adverse Events (AE) and Serious Adverse Events (SAE)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/ incapacity, is a congenital anomaly/ birth defect or other situations. The analysis was performed on Safety Population which comprised of all randomized participants who received at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received.</description>
        <time_frame>Up to Day 16 in each treatment period</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-serious Adverse Events (AE) and Serious Adverse Events (SAE)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/ incapacity, is a congenital anomaly/ birth defect or other situations. The analysis was performed on Safety Population which comprised of all randomized participants who received at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), and Aspartate Aminotransferase (AST) at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including ALT, ALP and AST.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), and Aspartate Aminotransferase (AST) at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including ALT, ALP and AST.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT; Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="10.23"/>
                    <measurement group_id="O2" value="15.6" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="7.09"/>
                    <measurement group_id="O2" value="14.0" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="8.98"/>
                    <measurement group_id="O2" value="16.7" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="7.07"/>
                    <measurement group_id="O2" value="14.9" spread="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" spread="12.85"/>
                    <measurement group_id="O2" value="74.8" spread="18.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="14.27"/>
                    <measurement group_id="O2" value="67.1" spread="15.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="17.58"/>
                    <measurement group_id="O2" value="80.9" spread="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" spread="16.96"/>
                    <measurement group_id="O2" value="76.9" spread="15.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="4.40"/>
                    <measurement group_id="O2" value="20.6" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="2.64"/>
                    <measurement group_id="O2" value="17.1" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="6.00"/>
                    <measurement group_id="O2" value="19.9" spread="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="3.75"/>
                    <measurement group_id="O2" value="17.8" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Urea Nitrogen (BUN) at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of BUN.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Urea Nitrogen (BUN) at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of BUN.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.354" spread="1.972"/>
                    <measurement group_id="O2" value="10.300" spread="4.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.945" spread="2.349"/>
                    <measurement group_id="O2" value="12.258" spread="2.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.841" spread="3.571"/>
                    <measurement group_id="O2" value="11.844" spread="2.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.041" spread="2.166"/>
                    <measurement group_id="O2" value="12.796" spread="1.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Calcium, Glucose, Potassium and Sodium at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including calcium, glucose, potassium and sodium.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Calcium, Glucose, Potassium and Sodium at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including calcium, glucose, potassium and sodium.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium;Period 1;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.393" spread="0.059"/>
                    <measurement group_id="O2" value="2.399" spread="0.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium;Period 1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.308" spread="0.068"/>
                    <measurement group_id="O2" value="2.304" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium;Period 2;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.364" spread="0.099"/>
                    <measurement group_id="O2" value="2.376" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium;Period 2;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.351" spread="0.087"/>
                    <measurement group_id="O2" value="2.378" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose;Period 1;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.684" spread="0.256"/>
                    <measurement group_id="O2" value="4.616" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose;Period 1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.728" spread="0.229"/>
                    <measurement group_id="O2" value="4.676" spread="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose;Period 2;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.521" spread="0.347"/>
                    <measurement group_id="O2" value="4.571" spread="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose;Period 2;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.851" spread="0.375"/>
                    <measurement group_id="O2" value="4.812" spread="0.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium;Period 1;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.86" spread="1.460"/>
                    <measurement group_id="O2" value="145.00" spread="1.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium;Period 1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.07" spread="1.439"/>
                    <measurement group_id="O2" value="141.43" spread="1.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium;Period 2;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.21" spread="1.251"/>
                    <measurement group_id="O2" value="141.50" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium;Period 2;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.43" spread="1.089"/>
                    <measurement group_id="O2" value="139.64" spread="1.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium;Period1;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.634" spread="0.457"/>
                    <measurement group_id="O2" value="4.404" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium;Period1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.522" spread="0.444"/>
                    <measurement group_id="O2" value="4.286" spread="0.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium;Period 2;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.371" spread="0.220"/>
                    <measurement group_id="O2" value="4.521" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium;Period 2;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.269" spread="0.334"/>
                    <measurement group_id="O2" value="4.555" spread="0.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Bilirubin (Total Bil), Direct Bilirubin (Direct Bil) and Creatinine (Creat) at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including total bil, direct bil and creat.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin (Total Bil), Direct Bilirubin (Direct Bil) and Creatinine (Creat) at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of clinical chemistry parameters including total bil, direct bil and creat.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creat; Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" spread="15.29"/>
                    <measurement group_id="O2" value="83.4" spread="15.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creat; Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="12.00"/>
                    <measurement group_id="O2" value="85.9" spread="15.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creat; Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" spread="14.31"/>
                    <measurement group_id="O2" value="78.5" spread="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creat; Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" spread="15.33"/>
                    <measurement group_id="O2" value="78.4" spread="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bil; Period1;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.14" spread="4.633"/>
                    <measurement group_id="O2" value="10.99" spread="6.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bil; Period1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="3.004"/>
                    <measurement group_id="O2" value="8.10" spread="6.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bil; Period2;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.90" spread="7.205"/>
                    <measurement group_id="O2" value="8.22" spread="3.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bil; Period2;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" spread="3.749"/>
                    <measurement group_id="O2" value="6.16" spread="2.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bil; Period1;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="1.294"/>
                    <measurement group_id="O2" value="4.01" spread="1.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bil; Period1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="0.959"/>
                    <measurement group_id="O2" value="2.93" spread="1.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bil; Period2;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="1.945"/>
                    <measurement group_id="O2" value="3.12" spread="1.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bil; Period2;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="1.149"/>
                    <measurement group_id="O2" value="2.49" spread="0.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Protein at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of total Protein.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Protein at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for the analysis of total Protein.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.34" spread="3.354"/>
                    <measurement group_id="O2" value="74.77" spread="4.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.90" spread="3.295"/>
                    <measurement group_id="O2" value="67.97" spread="2.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.76" spread="3.995"/>
                    <measurement group_id="O2" value="72.57" spread="3.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.64" spread="3.181"/>
                    <measurement group_id="O2" value="67.89" spread="4.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelets, Neutrophils, Monocytes, Lymphocytes, Leucocyte, Eosinophils and Basophils at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematology parameters including platelets, neutrophils, monocytes, lymphocytes, leucocyte, eosinophils and basophils.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelets, Neutrophils, Monocytes, Lymphocytes, Leucocyte, Eosinophils and Basophils at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematology parameters including platelets, neutrophils, monocytes, lymphocytes, leucocyte, eosinophils and basophils.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophil; Period 1;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.017"/>
                    <measurement group_id="O2" value="0.022" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophil; Period 1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.012"/>
                    <measurement group_id="O2" value="0.025" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophil; Period 2;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.012"/>
                    <measurement group_id="O2" value="0.029" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophil; Period 2;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.012"/>
                    <measurement group_id="O2" value="0.022" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophil; Period 1;Day-1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.136" spread="0.130"/>
                    <measurement group_id="O2" value="0.182" spread="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophil; Period 1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.146" spread="0.130"/>
                    <measurement group_id="O2" value="0.204" spread="0.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophil; Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.231" spread="0.230"/>
                    <measurement group_id="O2" value="0.139" spread="0.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophil; Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.253" spread="0.245"/>
                    <measurement group_id="O2" value="0.156" spread="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocyte; Period 1;Day-1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.458" spread="1.643"/>
                    <measurement group_id="O2" value="5.752" spread="0.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocyte; Period 1;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.369" spread="1.535"/>
                    <measurement group_id="O2" value="5.394" spread="1.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocyte; Period 2;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.736" spread="1.168"/>
                    <measurement group_id="O2" value="5.463" spread="1.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocyte; Period 2;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.887" spread="1.216"/>
                    <measurement group_id="O2" value="5.477" spread="1.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte; Period 1;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.127" spread="0.562"/>
                    <measurement group_id="O2" value="2.154" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte; Period 1;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.916" spread="0.453"/>
                    <measurement group_id="O2" value="2.039" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte; Period 2;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.328" spread="0.573"/>
                    <measurement group_id="O2" value="2.141" spread="0.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte; Period 2;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.186" spread="0.431"/>
                    <measurement group_id="O2" value="1.956" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Period 1;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.480" spread="0.123"/>
                    <measurement group_id="O2" value="0.470" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Period 1;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.464" spread="0.142"/>
                    <measurement group_id="O2" value="0.459" spread="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Period 2;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.461" spread="0.146"/>
                    <measurement group_id="O2" value="0.497" spread="0.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Period 2;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.475" spread="0.160"/>
                    <measurement group_id="O2" value="0.457" spread="0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils;Period 1;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.692" spread="1.293"/>
                    <measurement group_id="O2" value="2.924" spread="0.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils;Period 1;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.820" spread="1.289"/>
                    <measurement group_id="O2" value="2.667" spread="0.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils;Period 2;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.691" spread="0.697"/>
                    <measurement group_id="O2" value="2.657" spread="1.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils;Period 2;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.949" spread="0.848"/>
                    <measurement group_id="O2" value="2.885" spread="1.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Period 1;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.9" spread="61.98"/>
                    <measurement group_id="O2" value="264.4" spread="60.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Period 1;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.2" spread="65.74"/>
                    <measurement group_id="O2" value="244.5" spread="64.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Period 2;Day -1,24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.6" spread="61.65"/>
                    <measurement group_id="O2" value="289.6" spread="72.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Period 2;Day 2,24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.0" spread="56.04"/>
                    <measurement group_id="O2" value="274.2" spread="68.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Volume (MCV) at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCV.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Volume (MCV) at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCV.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.73" spread="2.834"/>
                    <measurement group_id="O2" value="84.86" spread="4.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.30" spread="2.796"/>
                    <measurement group_id="O2" value="84.50" spread="4.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.83" spread="4.975"/>
                    <measurement group_id="O2" value="85.97" spread="2.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.46" spread="4.878"/>
                    <measurement group_id="O2" value="85.41" spread="2.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Hemoglobin (MCH) at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCH.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Hemoglobin (MCH) at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCH.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Picogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.58" spread="1.212"/>
                    <measurement group_id="O2" value="29.44" spread="2.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.75" spread="1.295"/>
                    <measurement group_id="O2" value="29.51" spread="2.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.40" spread="2.242"/>
                    <measurement group_id="O2" value="29.68" spread="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.54" spread="2.112"/>
                    <measurement group_id="O2" value="29.75" spread="1.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Count at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of erythrocyte count.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Count at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of erythrocyte count.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.104" spread="0.451"/>
                    <measurement group_id="O2" value="5.020" spread="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.952" spread="0.387"/>
                    <measurement group_id="O2" value="4.871" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.006" spread="0.366"/>
                    <measurement group_id="O2" value="4.971" spread="0.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.838" spread="0.433"/>
                    <measurement group_id="O2" value="4.906" spread="0.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematocrit at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematocrit.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematocrit.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.437" spread="0.036"/>
                    <measurement group_id="O2" value="0.426" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.422" spread="0.033"/>
                    <measurement group_id="O2" value="0.411" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.424" spread="0.029"/>
                    <measurement group_id="O2" value="0.427" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.408" spread="0.036"/>
                    <measurement group_id="O2" value="0.419" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb) at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematology parameters including MCHC and Hb.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb) at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematology parameters including MCHC and Hb.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed</population>
          <units>Grams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCHC; Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.52" spread="1.030"/>
                    <measurement group_id="O2" value="34.68" spread="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC; Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.88" spread="1.084"/>
                    <measurement group_id="O2" value="34.89" spread="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC; Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.64" spread="1.100"/>
                    <measurement group_id="O2" value="34.54" spread="0.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC; Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.95" spread="1.097"/>
                    <measurement group_id="O2" value="34.82" spread="1.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb; Period 1;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.11" spread="1.554"/>
                    <measurement group_id="O2" value="14.79" spread="1.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb; Period 1;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.74" spread="1.391"/>
                    <measurement group_id="O2" value="14.38" spread="1.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb; Period 2;Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.70" spread="1.381"/>
                    <measurement group_id="O2" value="14.76" spread="1.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb; Period 2;Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.29" spread="1.578"/>
                    <measurement group_id="O2" value="14.60" spread="1.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reticulocytes at Indicated Time-points</title>
        <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of percent reticulocytes.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reticulocytes at Indicated Time-points</title>
          <description>Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of percent reticulocytes.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Percentage of reticulocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.786" spread="0.361"/>
                    <measurement group_id="O2" value="1.700" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.757" spread="0.384"/>
                    <measurement group_id="O2" value="1.571" spread="0.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day -1, 24 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.729" spread="0.397"/>
                    <measurement group_id="O2" value="1.886" spread="0.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.350" spread="2.176"/>
                    <measurement group_id="O2" value="1.743" spread="0.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potential Clinical Importance (PCI) Abnormal Findings for Urinalysis</title>
        <description>Urine samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2. PCI ranges for urinalysis parameters were as follows: specific gravity 1.001 to 1.035 kilogram per liter, blood negative (0 to 9) RBC per microliter, pH 4.6 to 8.0, protein negative (0.0 to 0.14) gram per liter, glucose negative (0 to 5.49) millimoles per liter, ketones negative (0.0 to 0.49) millimoles per liter, urobilinogen (0.0 to 1.0) milligrams per deciliter, urine leucocytes negative (0 to 14) leucocytes per microliter, Urine WBC, RBC and epithelial cells 0 to 5 high power per field.</description>
        <time_frame>Day -1 and Day 2 of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potential Clinical Importance (PCI) Abnormal Findings for Urinalysis</title>
          <description>Urine samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2. PCI ranges for urinalysis parameters were as follows: specific gravity 1.001 to 1.035 kilogram per liter, blood negative (0 to 9) RBC per microliter, pH 4.6 to 8.0, protein negative (0.0 to 0.14) gram per liter, glucose negative (0 to 5.49) millimoles per liter, ketones negative (0.0 to 0.49) millimoles per liter, urobilinogen (0.0 to 1.0) milligrams per deciliter, urine leucocytes negative (0 to 14) leucocytes per microliter, Urine WBC, RBC and epithelial cells 0 to 5 high power per field.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Rate at Indicated Time-points</title>
        <description>Respiratory rate of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
        <time_frame>Day 1 Pre-dose 1.5 hours, Day 1 post-dose 2, 4, and 6 hours and Day 2 post-dose 24 hours of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate at Indicated Time-points</title>
          <description>Respiratory rate of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="1.11"/>
                    <measurement group_id="O2" value="15.7" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="2.02"/>
                    <measurement group_id="O2" value="17.0" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="2.10"/>
                    <measurement group_id="O2" value="14.2" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="2.00"/>
                    <measurement group_id="O2" value="14.8" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="2.14"/>
                    <measurement group_id="O2" value="16.1" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="1.19"/>
                    <measurement group_id="O2" value="15.6" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="1.65"/>
                    <measurement group_id="O2" value="18.2" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="3.10"/>
                    <measurement group_id="O2" value="18.4" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="1.46"/>
                    <measurement group_id="O2" value="19.0" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="1.25"/>
                    <measurement group_id="O2" value="16.0" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate at Indicated Time-points</title>
        <description>Pulse rate of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
        <time_frame>Day 1 Pre-dose 1.5 hours, Day 1 post-dose 2, 4, and 6 hours and Day 2 post-dose 24 hours of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate at Indicated Time-points</title>
          <description>Pulse rate of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="7.95"/>
                    <measurement group_id="O2" value="58.1" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="8.17"/>
                    <measurement group_id="O2" value="55.1" spread="8.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="7.44"/>
                    <measurement group_id="O2" value="55.6" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="8.74"/>
                    <measurement group_id="O2" value="67.2" spread="12.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" spread="10.26"/>
                    <measurement group_id="O2" value="54.3" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="9.08"/>
                    <measurement group_id="O2" value="65.1" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" spread="8.88"/>
                    <measurement group_id="O2" value="63.1" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" spread="8.67"/>
                    <measurement group_id="O2" value="62.8" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="14.09"/>
                    <measurement group_id="O2" value="75.1" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="7.59"/>
                    <measurement group_id="O2" value="67.1" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature at Indicated Time-points</title>
        <description>Body temperature of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
        <time_frame>Day 1 Pre-dose 1.5 hours, Day 1 post-dose 2, 4, and 6 hours and Day 2 post-dose 24 hours of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature at Indicated Time-points</title>
          <description>Body temperature of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.19" spread="0.305"/>
                    <measurement group_id="O2" value="36.27" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.38" spread="0.333"/>
                    <measurement group_id="O2" value="36.23" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.48" spread="0.336"/>
                    <measurement group_id="O2" value="36.59" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.64" spread="0.303"/>
                    <measurement group_id="O2" value="36.79" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.29" spread="0.317"/>
                    <measurement group_id="O2" value="36.24" spread="0.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.28" spread="0.372"/>
                    <measurement group_id="O2" value="36.29" spread="0.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.51" spread="0.400"/>
                    <measurement group_id="O2" value="36.42" spread="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.58" spread="0.347"/>
                    <measurement group_id="O2" value="36.51" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.10" spread="0.421"/>
                    <measurement group_id="O2" value="36.63" spread="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.30" spread="0.321"/>
                    <measurement group_id="O2" value="36.11" spread="0.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time-points</title>
        <description>Blood pressure of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
        <time_frame>Day 1 Pre-dose 1.5 hours, Day 1 post-dose 2, 4, and 6 hours and Day 2 post-dose 24 hours of each treatment period</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SKF101804 Cefixime</title>
            <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Cefixime Reference Formulation</title>
            <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time-points</title>
          <description>Blood pressure of participants was measured on Day 1 and Day 2 of each treatment period 1 and 2 in a supine position after 5 minutes rest.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Period 1; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.6" spread="8.22"/>
                    <measurement group_id="O2" value="110.9" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 1; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.4" spread="7.30"/>
                    <measurement group_id="O2" value="111.3" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 1; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.3" spread="8.39"/>
                    <measurement group_id="O2" value="112.1" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 1; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.6" spread="7.17"/>
                    <measurement group_id="O2" value="108.6" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.9" spread="6.86"/>
                    <measurement group_id="O2" value="115.4" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 2; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.4" spread="3.97"/>
                    <measurement group_id="O2" value="111.2" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 2; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.1" spread="6.24"/>
                    <measurement group_id="O2" value="112.7" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 2; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.6" spread="8.53"/>
                    <measurement group_id="O2" value="111.1" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 2; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" spread="7.14"/>
                    <measurement group_id="O2" value="109.5" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.1" spread="6.24"/>
                    <measurement group_id="O2" value="113.6" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 1; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" spread="6.59"/>
                    <measurement group_id="O2" value="64.1" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 1; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" spread="7.69"/>
                    <measurement group_id="O2" value="60.9" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 1; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="5.43"/>
                    <measurement group_id="O2" value="63.3" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 1; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" spread="3.89"/>
                    <measurement group_id="O2" value="59.6" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 1; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="6.80"/>
                    <measurement group_id="O2" value="66.2" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 2; Day 1, 1.5 Hours Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.2" spread="10.09"/>
                    <measurement group_id="O2" value="61.8" spread="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 2; Day 1, 2 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" spread="7.65"/>
                    <measurement group_id="O2" value="63.1" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 2; Day 1, 4 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" spread="8.55"/>
                    <measurement group_id="O2" value="62.6" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 2; Day 1, 6 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="4.97"/>
                    <measurement group_id="O2" value="60.2" spread="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Period 2; Day 2, 24 Hours Post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="7.41"/>
                    <measurement group_id="O2" value="67.7" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and Non-serious adverse events (Non-SAEs) were collected from the start of the study treatment up to Day 16 in each treatment period.</time_frame>
      <desc>SAEs and Non-SAEs were reported by treatment for the Safety Population which comprised of all randomized participants who received at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>SKF101804 Cefixime</title>
          <description>Eligible participants received SKF101804 cefixime 200mg/5mL suspension (Test formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
        </group>
        <group group_id="E2">
          <title>Cefixime Reference Formulation</title>
          <description>Eligible participants received Cefixime 200mg/5mL suspension (Reference formulation), administered orally on Day 1 in each treatment period 1 or 2. The washout period was of at least 7 days and not more than 14 days between the treatment periods.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

